Flash Finance

Sai Parenterals LimitedSAIPARENTCorporate

Drug Manufacturers - General Latest results: Jun 2026 4 quarters of data
Consolidated Standalone
₹487.30
MCap ₹2,153 Cr
Sai Parenterals Limited — Stock analysis & AI research Sai Parenterals Limited — Multibagger AI analysis Sai Parenterals Limited — Seasonality — best & worst months Sai Parenterals Limited — Technical indicators & charts Sai Parenterals Limited — Technical setup — score, trend, support & resistance Sai Parenterals Limited — Live exchange announcements
📈 MACD Bearish Crossover📈 Bollinger Squeeze Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹179 Cr
Sales · Jun 2026
+435.1% YoY
₹24 Cr
Operating Profit · Jun 2026
+396.2% YoY
13.2%
OPM % · Jun 2026
-7.0% YoY
₹8 Cr
Net Profit · Jun 2026
+458.0% YoY
₹1.79
EPS · Jun 2026
+244.2% YoY

📝 Sai Parenterals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Sai Parenterals Limited reported revenue of ₹179 crore for the quarter ended June 2026 (Q1 FY27), up 435.1% from ₹33 crore in the same quarter last year, and down 9.8% sequentially over the March 2026 quarter.

Net profit rose 458.0% year-on-year to ₹8 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹1.79.

Operating profit stood at ₹24 crore — an operating margin (OPM) of 13.2%, compared with 14.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sai Parenterals Limited posted revenue of ₹327 crore, with a net profit of ₹7 crore.

Valuation snapshot

At the current price of ₹487.30, SAIPARENT has a market capitalisation of ₹2,153 crore.

Within the Drug Manufacturers - General industry, it is the 4th-largest of the 5 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.16%, foreign institutional investors (FIIs) 2.85%, domestic institutional investors (DIIs) 7.84%, public shareholders 38.15% of Sai Parenterals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,153 Cr
Current Price ?
₹487.3
P/E ?
N/A
Industry P/E ?
62.30
P/B ?
4.38
P/S ?
N/A
P/FCF ?
-11.70
Enterprise Value ?
₹2,486 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
6.0%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹179 Cr
PAT — latest qtr ?
₹8 Cr
YoY qtr sales growth ?
435.1%
YoY qtr profit growth ?
458.0%
Sales growth (3y) ?
58%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
48%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹333 Cr
Debt to Equity ?
0.68
Interest Coverage ?
0.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.16%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-12.4%
Return 6 months ?
1.5%

🗓️ Quarterly results (4 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 3396198179 +435.1% -9.8%
Operating Profit 5-42624 +396.2% -9.5%
Other Income 1334 +219.7% +24.7%
Interest 2589 +280.5% +17.0%
Depreciation 1688 +459.3% +1.4%
Profit Before Tax 2-121210 +389.5% -18.4%
Net Profit 1-7138 +458.0% -39.1%
EPS 0.52-1.802.981.79 +244.2% -39.9%
OPM % 14.2% -4.2% 13.1% 13.2% -7.0% +0.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric Prev FY FY26 TTM YoY %
Sales — ₹327 Cr — —
Operating Profit — ₹27 Cr — —
OPM % — 8.17% — —
NPM % — 2.27% — —
Other Income — ₹7 Cr — —
Depreciation — ₹15 Cr — —
Interest — ₹15 Cr — —
EBIT — ₹11 Cr — —
PBT — ₹2 Cr — —
Tax — — — —
Net Profit — ₹7 Cr — —
EPS — ₹1.70 — —
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 7131322 +69.2%
Reserves 246180469 +486.2%
Borrowings 6911994333 +254.3%
Other Liabilities 347585600 +605.9%
Total Liabilities 1342682721,424 +423.5%
Fixed Assets 447053364 +586.8%
CWIP 200212 —
Investments 0000 —
Other Assets 88198219848 +287.2%
Total Assets 1342682721,424 +423.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -13-303393 +181.8%
Cash from Investing Activity -19-460-274 —
Cash from Financing Activity 2479-36596 +1755.6%
Net Cash Flow -82-2415 +20850.0%
Free Cash Flow -30-7241-184 -548.8%
CFO/OP -54%-94%86%253% +194.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 231302283173 -38.9%
Inventory Days 83143199259 +30.2%
Days Payable 140203225224 -0.4%
Cash Conversion Cycle 174242256208 -18.8%
Working Capital Days 197279-161 -303.8%
ROCE % —16%17%6% -64.7%

👥 Shareholding (latest 4 periods)

Metric Mar 2026Apr 2026Jun 2026Sep 2026 % Chg
Promoters 51.16%51.16%51.16%51.16% +0.0%
FIIs 5.73%5.73%4.03%2.85% -29.3%
DIIs 12.86%12.86%8.53%7.84% -8.1%
Public 30.25%30.25%36.29%38.15% +5.1%
No. of Shareholders 7,6877,6879,31213,645 +46.5%

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 GLAXO GlaxoSmithKline Pharmaceuticals ₹2,818.90 47,754 44.7 3,955 1,068 40.8% 27.0% 1.9% 11.6% 16.6% 15.7%
2 RUBICON RUBICON RESEARCH ₹1,839.40 30,367 103.7 1,936 288 23.3% 14.9% — — 51.8% 97.2%
3 PFIZER Pfizer ₹4,055.00 18,551 25.2 2,569 735 36.7% 28.6% 10.4% -5.8% 8.3% 6.2%
4 SAIPARENT Sai Parenterals ₹498.00 2,200 — — — — — — — 435.1% 458.0%
5 SYMBIOTEC Symbiotec Pharmalab ₹1,107.00 — — — — — — — — 7.5% -53.1%
❓ Frequently asked questions
What was Sai Parenterals Limited's revenue in Q1 FY27?
Sai Parenterals Limited reported revenue of ₹179 crore for the quarter ended June 2026 (Q1 FY27), up 435.1% from ₹33 crore in the same quarter last year, and down 9.8% sequentially over the March 2026 quarter.
What was Sai Parenterals Limited's net profit in Q1 FY27?
Net profit rose 458.0% year-on-year to ₹8 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹1.79.
What is SAIPARENT's market capitalisation and P/E ratio?
At the current price of ₹487.30, SAIPARENT has a market capitalisation of ₹2,153 crore.
Who owns Sai Parenterals Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.16%, foreign institutional investors (FIIs) 2.85%, domestic institutional investors (DIIs) 7.84%, public shareholders 38.15% of Sai Parenterals Limited.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI